NSEIssue of Securities1d ago · 30 Oct 2026, 03:18 pm

Issue of Securities

Sudarshan Pharma Industries Limited · SUDARSHAN

✦ AI SummaryFundraise

Sudarshan Pharma Industries Limited has informed the Exchange about issue of Securities, specifically the proposal to raise funds through the issue and allotment of up to 72,00,00,000 warrants convertible into equity shares at a price to be determined, subject to regulatory approvals and shareholder approval at an EGM.

Analysis Scores

Earnings Impact5/10
Growth Catalyst6/10
Governance Concern2/10
Regulatory Risk4/10
Balance Sheet Risk3/10
Liquidity Impact7/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Sudarshan Pharma Industries Limited has informed the Exchange about issue of Securities

Attachments (1)

📄

SUDARSHAN_30102026151743_Sudarshan_Outcome_Warrants_BM_30_10_2026.pdf

pdf

Download →
View document text
EUDAREHAI PHAR]IA IIIDUOTRIET TTD Head Otlice : 301. Aura Biplex, Premium Retail Premises, 7, S.V Boad Borival (West), Nlurnba '400092 E-mail : comp iance@sudarshanpharma.com Website : www.sudarshanpharma.com BoardLine: i91 22-42221111 i43331111 i42221116 (100 line) . CIN : 151496[,1H200BPLC1 84997 sP L/ CS/SE/ 2A26-2O2t /12 Date: 3olh October 2026 The Ljsting Department The [isting Department BSE Limited National Stock Exchange of lndia Limited, Phlroze.leejeebhoy Towers, Exchange Plaza, C 1, Block G, Da alStreet, Bandra Kurla Complex, Bandra (E), Mumbai 400 001 Mumbai- 400 051 BSE Scrip Code: 543828 NSE Trading Symbol: SUDARSHAN Ref: Regulation 30 ofSEB| (Listing Obligations And Disclosure Requirements) Regulations, 2015 Sub: Out.ome of the Meeting of Board of Dire.tors of the Company held on Thursday, 29rh October, 2026 Dea r Sir / Madam, This s to lnform you that the Board of Directors of the Company at its Board meeting held on 291' October, 2026 has approved the proposa to raising of fLrnds through issue and alotment of up to 72,00,00,000 (Sevefty Two Crores) Warrafts, each Warrant coovertible into 1(one) Equity Share of thef-a.eVaueof Re.1/ (RupeeOneOnly) ntermsofChapterVoftheSEBl (tssue of Capital and Dsclosure Requlrements) Regulations, 2018, as amended ("5EBl ICDR Regulations") on a preferent a basisto N/lr. Hemal Mehta and Mr. Sachin Mehta, Promoters of the Company at a price to be determined as per Regulation 164 of the SEBt |CDR Regulations, subject to the approval of regu atory / statutory authorities and the members of the Company at an Extraordinary General [/]eetlng ("EGM"). The Board wi I be seeklng shareholders' approval in an EGM, Notice of whlch will be issued separately. The meeting of the Board of Directors commenced at 7.00 pm and concluded at 10.00 pm We request you to klndly take the above informatlon on record Thanl(s & Regards, You rs faithfully, For Sudarshan Pharma lndustries Sach n Mehta ,9 Joint Managing Director Regd. Off. : 301, Aura Biplex, Above Kalyan Jewellers, S.V Road, Borivali (West), [,4umbai -400092